Pharmaceuticals Global On demand · 24-48h

Global Burns and Scalds Treatment Market Strategic Research Report

Global Burns and Scalds Treatment Market Strategic Research …
$3,500 USD
Market Research Reports
Strategic Research Report
Global Burns and Scalds Treatment Market
$2.57B2025
3.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Salve, Spray, Oil, Other

By Application: Hospitals and Clinics, Retail Pharmacies, E-commerce Platforms, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: MEBO, B. Braun, Integra LifeSciences, Tianjin Pharmaceutical Da Ren Tang Group Corporation, Smith & Nephew, Yangtze River Pharmaceutical, STADA Thornton & Ross, Kenvue Brands LLC, Changchun OVERSEAS, Orkla Health, Guangdong Hengjian Investment, Otsuka Pharmaceutical Co, Tonghua Maoxiang Medical Co, Cipla, Mitsubishi Tanabe Pharma Corporation, Chongqing GankyilL Bio-Technology, Quest Products, LLC, Jianmin Pharmaceutical Group Co, Acme United Corp., Dongwha Pharm, CR Pharmaceutical Commercial Group Co, Safetec Of America, Chongqing Taiji Industry, North China Pharmaceutical Co, Xiangxi Hongcheng, Aoxing Pharmaceutical, Jilin Aodong Pharmaceutical Group Co, Beijing Tong Ren Tang Chinese Medicine Co

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 180 pages
Market size 2025
$2.57B
Billion USD
Forecast CAGR
3.6%
2025-2032
Forecast 2032
$3.3B
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

Scope of the Report

The global Burns and Scalds Treatment market size is predicted to grow from US$ 2,570 million in 2025 to US$ 3,314 million in 2032; it is expected to grow at a CAGR of 3.6% from 2026 to 2032.

In 2025, the global production volume of Burns and Scalds Treatment products reached approximately 135 million units, with an average selling price of USD 18.5 per unit, production capacity of approximately 185 million units, and a gross margin of 42%.

Burns and Scalds Treatment refers to therapeutic products and related wound-care products used for skin and soft-tissue thermal injuries caused by flames, hot liquids, steam, contact with hot objects, and other heat sources. Major products include burn ointments and creams, gels, sprays, and burn wound dressings. These products are primarily used to protect wounds, maintain an appropriate wound-healing environment, relieve local discomfort, and support wound repair. Depending on the depth and severity of the burn, they are used across home first aid, outpatient clinics, hospitals, and specialized burn care settings.

The Burns and Scalds Treatment market is mainly driven by demand arising from household accidents, industrial accidents, kitchen and food-service scalds, fires, and other thermal injuries. The product mix is gradually expanding from traditional burn ointments, creams, and basic dressings toward advanced wound-care products such as hydrogels, foam dressings, and antimicrobial dressings. Hospitals place greater emphasis on infection control, wound-healing performance, and ease of dressing changes, while the home-care market focuses more on convenience and immediate first-aid treatment. With continued advances in wound-care technologies and improved burn wound management in healthcare institutions, the penetration of higher-value advanced dressings and professional burn-care products is expected to increase further.

This report presents a comprehensive overview of the global Burns and Scalds Treatment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Salve
  • Spray
  • Oil
  • Other

Segment by Treatment Product Type

  • Burn Ointments and Creams
  • Burn Dressings
  • Burn Sprays and Gels
  • Others

Segment by Burn Depth

  • Superficial Burns (First-degree)
  • Superficial Partial-thickness Burns (Superficial Second-degree)
  • Deep Partial-thickness Burns (Deep Second-degree)
  • Full-thickness Burns (Third-degree)

Segment by Application

  • Hospitals and Clinics
  • Retail Pharmacies
  • E-commerce Platforms
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Burns and Scalds Treatment market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospitals and Clinics, Retail Pharmacies, E-commerce Platforms evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Burns and Scalds Treatment Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 3.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$2.57B
2025
Forecast
$3.3B
2032
CAGR
3.6%
2025–2032
Области
5
global
Key companies
MEBOB. BraunIntegra LifeSciencesTianjin Pharmaceutical Da Ren Tang Group CorporationSmith & NephewYangtze River PharmaceuticalSTADA Thornton & RossKenvue Brands LLC
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
SalveSprayOilOther
By Application
Hospitals and ClinicsRetail PharmaciesE-commerce PlatformsOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Salve
  • 3.1.3 Spray
  • 3.1.4 Oil
  • 3.1.5 Other
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospitals and Clinics
  • 4.1.3 Retail Pharmacies
  • 4.1.4 E-commerce Platforms
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 MEBO
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 B. Braun
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Integra LifeSciences
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Tianjin Pharmaceutical Da Ren Tang Group Corporation
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Smith & Nephew
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Yangtze River Pharmaceutical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 STADA Thornton & Ross
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Kenvue Brands LLC
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Changchun OVERSEAS
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Orkla Health
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Guangdong Hengjian Investment
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Otsuka Pharmaceutical Co
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Tonghua Maoxiang Medical Co
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Cipla
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Mitsubishi Tanabe Pharma Corporation
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Chongqing GankyilL Bio-Technology
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Quest Products, LLC
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Jianmin Pharmaceutical Group Co
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Acme United Corp.
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Dongwha Pharm
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 CR Pharmaceutical Commercial Group Co
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Safetec Of America
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Chongqing Taiji Industry
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 North China Pharmaceutical Co
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Xiangxi Hongcheng
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Aoxing Pharmaceutical
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 Jilin Aodong Pharmaceutical Group Co
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 Beijing Tong Ren Tang Chinese Medicine Co
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Burns and Scalds Treatment market size?
The global Burns and Scalds Treatment market is estimated at US$ 2.57 billion in 2025 (base year) and is projected to reach US$ 3.31 billion by 2032.
What growth rate is expected for the Burns and Scalds Treatment market through 2032?
The market is expected to grow at a CAGR of 3.6% from 2026 to 2032, expanding from US$ 2.57 billion in 2025 to US$ 3.31 billion in 2032, roughly 1.3 times its base-year value.
How is Burns and Scalds Treatment defined?
In 2025, the global production volume of Burns and Scalds Treatment products reached approximately 135 million units, with an average selling price of USD 18.5 per unit, production capacity of approximately 185 million units, and a gross margin of 42%.
What are the main segments of the Burns and Scalds Treatment market by type?
By type, the market is segmented into Salve, Spray, Oil and Other.
Which applications drive demand in the Burns and Scalds Treatment market?
Key applications covered include Hospitals and Clinics, Retail Pharmacies, E-commerce Platforms and Other.
Who are the key players in the Burns and Scalds Treatment market?
Key players profiled include MEBO, B. Braun, Integra LifeSciences, Tianjin Pharmaceutical Da Ren Tang Group Corporation, Smith & Nephew, Yangtze River Pharmaceutical, STADA Thornton & Ross and Kenvue Brands LLC, among 28 companies covered in total.
Which regions and countries are covered for Burns and Scalds Treatment?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Burns and Scalds Treatment market?
The Burns and Scalds Treatment market is mainly driven by demand arising from household accidents, industrial accidents, kitchen and food-service scalds, fires, and other thermal injuries.
Who should buy the Burns and Scalds Treatment market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospitals and Clinics, Retail Pharmacies and E-commerce Platforms, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Burns and Scalds Treatment market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.